See more : Roularta Media Group NV (ROU.BR) Income Statement Analysis – Financial Results
Complete financial analysis of ProQR Therapeutics N.V. (PRQR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProQR Therapeutics N.V., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Algoma Steel Group Inc. (ASTL) Income Statement Analysis – Financial Results
- Yamashin-Filter Corp. (YMFCF) Income Statement Analysis – Financial Results
- Sarda Energy & Minerals Limited (SARDAEN.BO) Income Statement Analysis – Financial Results
- Nitin Spinners Limited (NITINSPIN.NS) Income Statement Analysis – Financial Results
- SRP Groupe S.A. (SRP.PA) Income Statement Analysis – Financial Results
ProQR Therapeutics N.V. (PRQR)
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 4.04M | 1.35M | 0.00 | 1.93M | 4.94M | -1.53M | 2.28M | 9.41M | 313.00K | 0.00 |
| Cost of Revenue | 133.52K | 2.48M | 0.00 | 2.19M | 116.82M | 983.51K | 1.00M | 1.28M | 482.85K | 0.00 | 0.00 |
| Gross Profit | 6.38M | 1.56M | 1.35M | -2.19M | -114.89M | 3.96M | -2.53M | 1.00M | 8.92M | 313.00K | 0.00 |
| Gross Profit Ratio | 97.95% | 38.68% | 100.00% | 0.00% | -5,943.61% | 80.09% | 165.49% | 43.84% | 94.87% | 100.00% | 0.00% |
| Research & Development | 25.15M | 50.87M | 42.22M | 38.14M | 46.49M | 29.51M | 31.15M | 31.92M | 23.40M | 10.27M | 2.57M |
| General & Administrative | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Other Expenses | -3.01M | -765.00K | -1.04M | 9.37M | 1.93M | 5.76M | 1.50M | 1.83M | 3.24M | 313.00K | 0.00 |
| Operating Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Cost & Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Interest Income | 2.59M | 106.00K | 5.00K | 313.00K | 402.00K | -792.00K | -3.18M | 470.00K | 6.17M | 4.33M | 24.00K |
| Interest Expense | 1.20M | 5.13M | 3.41M | 2.04M | 1.08M | 810.00K | 596.00K | 538.00K | 395.00K | 265.00K | 38.00K |
| Depreciation & Amortization | 2.51M | 2.48M | 2.42M | 2.19M | 2.05M | 983.51K | 1.00M | 1.28M | 480.00K | 126.00K | 24.00K |
| EBITDA | -24.10M | -56.46M | -54.95M | -136.56M | -174.27M | -35.29M | 0.00 | -120.55M | -84.24M | -49.70M | -3.19M |
| EBITDA Ratio | -369.93% | -1,470.99% | -4,089.81% | 0.00% | -2,965.65% | -831.05% | 2,676.78% | -1,759.68% | -316.34% | -5,318.85% | 0.00% |
| Operating Income | -31.86M | -64.72M | -57.19M | -42.37M | -57.45M | -36.29M | -40.50M | -39.57M | -27.00M | -16.46M | -3.24M |
| Operating Income Ratio | -489.09% | -1,603.07% | -4,223.86% | 0.00% | -2,971.81% | -734.53% | 2,648.66% | -1,734.14% | -287.05% | -5,259.11% | 0.00% |
| Total Other Income/Expenses | 4.05M | 1.05M | -3.47M | -4.12M | 117.65M | -792.00K | 850.31K | 470.00K | 6.17M | 4.33M | -14.00K |
| Income Before Tax | -27.81M | -64.80M | -61.56M | -46.49M | -56.61M | -37.09M | -43.67M | -39.10M | -20.83M | -12.13M | -3.25M |
| Income Before Tax Ratio | -426.97% | -1,605.03% | -4,546.75% | 0.00% | -2,928.82% | -750.56% | 2,856.31% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| Income Tax Expense | -78.00K | 96.00K | 117.00K | 124.00K | 132.00K | 1.00K | 2.00K | -470.00K | -6.17M | -4.33M | 24.00K |
| Net Income | -28.12M | -64.89M | -61.68M | -46.61M | -56.75M | -36.89M | -43.64M | -39.10M | -20.83M | -12.13M | -3.25M |
| Net Income Ratio | -431.67% | -1,607.41% | -4,555.39% | 0.00% | -2,935.64% | -746.69% | 2,853.96% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| EPS | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| EPS Diluted | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| Weighted Avg Shares Out | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
| Weighted Avg Shares Out (Dil) | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
ProQR Announces Second Quarter 2023 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today reported its financial...
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
ProQR: Too Many Failures For Its RNA Technology
PRQR, last year, failed a pivotal trial. This is the third time it has failed trials after showing early signs of efficacy. While they are making an effort, I see little future here.
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced a presentation...
ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.22 per share a year ago.
ProQR Announces Upcoming Investor Conferences in April and May
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company...
Why Shares of ProQR Therapeutics Dropped on Wednesday
ProQR focuses on RNA cell-editing therapies to treat rare diseases. The company lost roughly $117 million in cash in 2022.
ProQR to Present at Upcoming Scientific and Industry Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced several presentations highlighting the Company's proprietary Axiomer® RNA editing technology platform...
5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts
Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information |...
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.
Source: https://incomestatements.info
Category: Stock Reports